130 related articles for article (PubMed ID: 26044651)
1. Growth inhibitory effect of adenovirus-mediated tissue-targeted expression of ribosomal protein L23 on human colorectal carcinoma cells.
Fang H; Kang J; Du R; Zhao X; Zhang X; Ren D; Zhang Y; Lu Z; Wu S; Zheng W; Wen J
Oncol Rep; 2015 Aug; 34(2):763-70. PubMed ID: 26044651
[TBL] [Abstract][Full Text] [Related]
2. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer.
Zhang YF; Zhang BC; Zhang AR; Wu TT; Liu J; Yu LF; Wang WX; Gao JF; Fang DC; Rao ZG
Oncol Rep; 2013 Oct; 30(4):1989-95. PubMed ID: 23933826
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
4. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene.
Shen LZ; Wu WX; Xu DH; Zheng ZC; Liu XY; Ding Q; Hua YB; Yao K
World J Gastroenterol; 2002 Apr; 8(2):270-5. PubMed ID: 11925606
[TBL] [Abstract][Full Text] [Related]
5. Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis.
Liu S; Tackmann NR; Yang J; Zhang Y
Oncogene; 2017 Mar; 36(10):1374-1383. PubMed ID: 27617574
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein.
Harris MP; Sutjipto S; Wills KN; Hancock W; Cornell D; Johnson DE; Gregory RJ; Shepard HM; Maneval DC
Cancer Gene Ther; 1996; 3(2):121-30. PubMed ID: 8729911
[TBL] [Abstract][Full Text] [Related]
7. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
8. RPL23 Links Oncogenic RAS Signaling to p53-Mediated Tumor Suppression.
Meng X; Tackmann NR; Liu S; Yang J; Dong J; Wu C; Cox AD; Zhang Y
Cancer Res; 2016 Sep; 76(17):5030-9. PubMed ID: 27402081
[TBL] [Abstract][Full Text] [Related]
9. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
10. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
11. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
[TBL] [Abstract][Full Text] [Related]
12. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
[TBL] [Abstract][Full Text] [Related]
13. Triptolide interrupts rRNA synthesis and induces the RPL23‑MDM2‑p53 pathway to repress lung cancer cells.
Wang J; Zhang ZQ; Li FQ; Chen JN; Gong X; Cao BB; Wang W
Oncol Rep; 2020 Jun; 43(6):1863-1874. PubMed ID: 32236588
[TBL] [Abstract][Full Text] [Related]
14. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
15. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition.
Dai MS; Zeng SX; Jin Y; Sun XX; David L; Lu H
Mol Cell Biol; 2004 Sep; 24(17):7654-68. PubMed ID: 15314173
[TBL] [Abstract][Full Text] [Related]
16. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
17. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
[TBL] [Abstract][Full Text] [Related]
18. Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma.
Koom WS; Park SY; Kim W; Kim M; Kim JS; Kim H; Choi IK; Yun CO; Seong J
J Radiat Res; 2012; 53(2):202-10. PubMed ID: 22510592
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers.
Jiang GL; Huang S
Cancer Res; 2001 Mar; 61(5):1796-8. PubMed ID: 11280725
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Min SH; Kim DM; Heo YS; Kim HM; Kim IC; Yoo OJ
Life Sci; 2010 Jan; 86(1-2):66-72. PubMed ID: 19945467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
